ZURICH - Sickle cell disease drugs made by Novartis and Global Blood Therapeutics may not be cost effective at current prices, a draft report published on Friday suggested, widening the debate over U.S. healthcare affordability.
The finding that the costs of all three medicines would likely have to be slashed to achieve acceptable cost-effectiveness thresholds comes as Congress and U.S. President Donald Trump weigh action over high healthcare costs.ICER said it concluded that Adakveo’s annual cost should be $25,410, down from an estimated $88,000 bill, and that Oxbryta must be trimmed to $9,218 from about $84,000, to meet cost-effectiveness thresholds.
At the current estimated costs for Adakveo, Oxbryta and Endari, all the QALYs exceeded $1 million, ICER said, well above the $150,000 the group ordinarily considers an appropriate cost-effectiveness threshold. “We look forward to gaining a better understanding of the approach ICER used to make its assessment and to helping them better understand the value of Adakveo,” Novartis said.San Francisco-based GBT contended that ICER’s review conflicts with the U.S. Food and Drug Administration’s goal of speeding medicines to patients.
The medications will never be affordable because of who they are targeting. Society thrives on stripping black people of all they have on a daily basis.
I don’t know for sure, but I’m guessing that successful gene splicing has quashed Novartis effort at a sickle cell drug. On to other unreasonably expensive drugs for a host of other illnesses.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: latimes - 🏆 11. / 82 Read more »
Source: latimes - 🏆 11. / 82 Read more »
Source: trtworld - 🏆 101. / 63 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: NYMag - 🏆 111. / 63 Read more »